81 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Elastic Nv (ESTC) CEO and Chairman Shay Banon Sold $820,000 of Shares http://www.gurufocus.com/news/941121/elastic-nv-estc-ceo-and-chairman-shay-banon-sold-820000-of-shares Sep 04, 2019 - Elastic Nv (ESTC) CEO and Chairman Shay Banon Sold $820,000 of Shares, Stocks: ESTC, release date:Sep 04, 2019
Novartis Inks Commercialization Deal for Tysabri Biosimilar http://www.zacks.com/stock/news/501408/novartis-inks-commercialization-deal-for-tysabri-biosimilar?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-501408 Sep 04, 2019 - Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503575 Sep 05, 2019 - AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
FDA Grants Priority Review to Global Blood's SCD Candidate http://www.zacks.com/stock/news/505290/fda-grants-priority-review-to-global-bloods-scd-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-505290 Sep 06, 2019 - The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe http://www.zacks.com/stock/news/512573/allergans-filings-for-abicipar-pegol-accepted-in-us-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-512573 Sep 11, 2019 - The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
4 Big Drugmakers Boasting Impressive Oncology Pipelines http://www.zacks.com/stock/news/513001/4-big-drugmakers-boasting-impressive-oncology-pipelines?cid=CS-ZC-FT-analyst_blog|industry_focus-513001 Sep 11, 2019 - We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance http://www.zacks.com/stock/news/515058/puma-biotechs-snda-for-nerlynx-combo-gets-fda-acceptance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-515058 Sep 12, 2019 - The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
Adverum Reports Data From Phase I Wet AMD Study, Stock Down http://www.zacks.com/stock/news/516878/adverum-reports-data-from-phase-i-wet-amd-study-stock-down?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-516878 Sep 13, 2019 - Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis http://www.zacks.com/stock/news/522810/jj-files-sbla-for-tremfya-with-fda-for-psoriatic-arthritis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-522810 Sep 17, 2019 - J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval http://www.zacks.com/stock/news/532246/novo-nordisks-semaglutide-in-tablet-form-gets-fda-approval?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-532246 Sep 23, 2019 - Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.

Pages: 123456...9

Page 1>